March 2024 Patent Highlights: OX2R Agonists, TEAD Covalent Inhibitors, NaV1.8 Inhibitors, LRRK2 Inhibitors, and More

In this article, we present a curated selection of over 60 molecules from September that caught our attention, along with highlights of our top picks and insights into why they stand out.

This October roundup features key clinical updates, including FDA approvals, significant trial results for major drug candidates, the initiation of new clinical trials, and updates on halted studies.

This article highlights a patent application from Puhe BioPharma that discloses the biological activity of compounds that act as WRN helicase inhibitors, providing a summary of key data for selected molecules disclosed in the patent application.

To help you quickly scan the patent literature, we’ve distilled down thousands of new documents into a searchable table of over 200 selected patents focused on key areas in drug discovery, all published in June 2024. This resource is enriched with detailed highlights on selected molecules targeting high-interest areas such as synthetically lethal Polθ inhibitors, SARM1 inhibitors for neurodegenerative indications, and our best guess at the identity of Gilead’s small molecule GLP-1R agonist GS-4571

Check out our searchable, annotated database featuring our curated selection of the most important drug discovery patents published in October 2024.